Mouse COL1(Collagen Type Ⅰ) ELISA Kit
中文名称:小鼠Ⅰ型胶原(COL1)酶联免疫吸附测定试剂盒
别称:
Price:
Size:
96T
48T
96T*5
- 反应性: Mouse
- 检测范围: 0.31-20 ng/mL
- 灵敏度: 0.19 ng/mL
产品应用 | ELISA |
检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗小鼠COL1抗体包被于酶标板上,实验时样品(或标准品)中的小鼠COL1会与包被抗体结合。后依次加入生物素化的抗小鼠COL1抗体和辣根过氧化物酶标记的亲和素,抗小鼠COL1抗体与结合在包被抗体上的小鼠COL1结合,生物素与亲和素特异性结合而形成免疫复合物,游离的成分被洗去。加入显色底物(TMB),TMB在辣根过氧化物酶的催化下呈现蓝色,加终止液后变成黄色。用酶标仪在450 nm波长处测OD值,COL1浓度与OD450值之间呈正比,通过绘制标准曲线计算出样品中COL1的浓度。 |
反应类型 | Sandwich-ELISA |
规格 |
96T
/ 48T
/ 96T*5
|
反应时间 | 3.5h |
反应性 | Mouse |
检测方法 | 比色法;ELISA;夹心法 |
检测范围 | 0.31-20 ng/mL |
灵敏度 | 0.19 ng/mL |
样本体积 | 100μL |
样本类型 | 血清,血浆,细胞上清,细胞提取液体,组织匀浆等其他生物体液 |
特异性 | 可检测样本中的小鼠COL1,且与其它类似物无明显交叉反应 |
精密度 | 板内,板间变异系数均<10% |
回收率 | 80%-120% |
储存条件 | 2-8℃/-20℃ |
数据处理 |
-
A Chinese Herbal Formula Ameliorates Pulmonary Fibrosis by Inhibiting Oxidative Stress via Upregulating Nrf2
IF: 5.811Journal:Frontiers in Pharmacology -
Metformin attenuates post‐epidural fibrosis by inhibiting the TGF‐β1/Smad3 and HMGB1/TLR4 signaling pathways
IF: 5.31Journal:JOURNAL OF CELLULAR AND MOLECULAR MEDICINE -
Insight into delivery of dermal fibroblast by non-biodegradable bacterial nanocellulose composite hydrogel on wound healing
IF: 5.162Journal:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES -
Epithelial-Mesenchymal Transition in Asthma Airway Remodeling Is Regulated by the IL-33/CD146 Axis
IF: 5.085 -
The role of Hrd1 in ultraviolet (UV) radiation induced photoaging
IF: 4.831 -
IL-33 Promotes ST2-Dependent Fibroblast Maturation via P38 and TGF-β in a Mouse Model of Epidural Fibrosis
IF: 4.169 -
In vitro and in vivo efficacy of thiacloprid against Echinococcus multilocularis
IF: 3.876 -
Salvia miltiorrhiza Restrains Reactive Oxygen Species-Associated Pulmonary Fibrosis via Targeting Nrf2-Nox4 Redox Balance
IF: 3.51Journal:AMERICAN JOURNAL OF CHINESE MEDICINE -
Long Noncoding RNA NORAD Promotes Fracture Healing through Interacting with Osteoblast Differentiation via Targeting miR-26a
IF: 3.246Journal:Biomed Research International -
MicroRNA-455–3p promotes osteoblast differentiation via targeting HDAC2
IF: 2.687Journal:INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED